Angle (AGL) RNS Announcements

Add to Alert list
Date Time Source Announcement
25 Mar 2022 07:00 AM
RNS
Identifying therapeutic targets in TNBC patients
15 Mar 2022 07:00 AM
RNS
Update on laboratory accreditation
09 Mar 2022 04:41 PM
RNS
Second Price Monitoring Extn
09 Mar 2022 04:36 PM
RNS
Price Monitoring Extension
02 Mar 2022 06:29 PM
RNS
Holding(s) in Company
18 Feb 2022 05:13 PM
RNS
Issue of Equity
21 Jan 2022 07:00 AM
RNS
Potential in immunotherapy treatment selection
17 Jan 2022 07:00 AM
RNS
Concordance of Parsortix with tissue biopsy
13 Jan 2022 07:00 AM
RNS
Update on lab accreditation and ovarian study
10 Jan 2022 07:00 AM
RNS
Insight into drug resistance in NSCLC
22 Dec 2021 06:29 PM
RNS
Issue of Equity
01 Dec 2021 06:11 PM
RNS
Issue of Equity
01 Dec 2021 07:00 AM
RNS
Parsortix in RNA analysis of CTCs as tool in NSCLC
26 Nov 2021 05:33 PM
RNS
Issue of Equity
17 Nov 2021 10:32 AM
RNS
Issue of Equity
15 Nov 2021 07:00 AM
RNS
Issue of LTIP Options and Share Options
15 Nov 2021 07:00 AM
RNS
Appointment of Chief Medical Officer
12 Nov 2021 05:51 PM
RNS
Issue of Equity
12 Nov 2021 07:00 AM
RNS
Participation at Jefferies healthcare conference
11 Nov 2021 07:00 AM
RNS
Parsortix system showcased at NCRI Festival
10 Nov 2021 05:40 PM
RNS
Issue of Equity
02 Nov 2021 07:00 AM
RNS
Change of Adviser
21 Oct 2021 05:25 PM
RNS
Issue of Equity
15 Oct 2021 05:45 PM
RNS
Issue of Equity
30 Sep 2021 04:02 PM
RNS
Issue of Equity
30 Sep 2021 07:00 AM
RNS
Interim Results
27 Sep 2021 07:00 AM
RNS
Parsortix demonstrates ability to isolate CTCs
22 Sep 2021 07:00 AM
RNS
Study shows use of Parsortix to assess PD-L1
20 Sep 2021 07:00 AM
RNS
Parsortix enables gene expression analysis in mPCa
07 Sep 2021 07:00 AM
RNS
Notice of Interim Results and Webcast
24 Aug 2021 07:00 AM
RNS
Director/PDMR Shareholding
09 Aug 2021 07:00 AM
RNS
Study highlights superior performance of Parsortix
06 Aug 2021 01:17 PM
RNS
Issue of Equity
03 Aug 2021 03:13 PM
RNS
Issue of Equity
28 Jul 2021 07:00 AM
RNS
Contract secured for bespoke assay development
09 Jul 2021 07:00 AM
RNS
Harvesting CTCs from brain metastasis patients
07 Jul 2021 06:34 PM
RNS
Director/PDMR Shareholding
02 Jul 2021 10:45 AM
RNS
Issue of Equity
30 Jun 2021 03:44 PM
RNS
Result of AGM
25 Jun 2021 07:00 AM
RNS
Result of Accelerated Bookbuild
24 Jun 2021 06:28 PM
RNS
Accelerated bookbuild to raise up to £20m
18 Jun 2021 11:42 AM
RNS
Annual General Meeting update
18 Jun 2021 07:00 AM
RNS
ctDNA and CTCs have differences in EGFR mutations
04 Jun 2021 07:00 AM
RNS
Update on submission for FDA clearance
01 Jun 2021 07:00 AM
RNS
Potential to prevent breast cancer relapse
20 May 2021 07:00 AM
RNS
Parsortix demonstrates oesophageal cancer utility
19 May 2021 04:37 PM
RNS
Exercise of options and total voting rights
11 May 2021 07:00 AM
RNS
Parsortix study uncovers targets in TNBC patients
30 Apr 2021 11:22 AM
RNS
Exercise of options and total voting rights
29 Apr 2021 07:00 AM
RNS
Preliminary Results

ANGLE PLC is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. The Company's product includes Parsortix cell separation system.

Founded in 1994, Angle listed on LSE in 2004 under the ticker AGL.

UK 100

Latest directors dealings